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The glucocorticoid (GC) receptor (GR), when liganded
toGC,activates transcription throughdirect binding to
simple (+)GRE DNA binding sequences (DBS). GC-in-
duced direct repression via GR binding to complex
‘‘negative’’ GREs (nGREs) has been reported.
However,GR-mediated transrepressionwasgenerally
ascribed to indirect ‘‘tethered’’ interaction with other
DNA-bound factors.We report that GC-induces direct
transrepression via the binding of GR to simple DBS
(IR nGREs) unrelated to (+)GRE. These DBS act on
agonist-liganded GR, promoting the assembly of cis-
acting GR-SMRT/NCoR repressing complexes. IR
nGREs are present in over 1000 mouse/human ortho-
log genes, which are repressed by GC in vivo. Thus
variations in the levels of a single ligand can coordi-
nately turngenesonor off depending in their response
elementDBS, allowing an additional level of regulation
in GR signaling. This mechanism suits GR signaling
remarkably well, given that adrenal secretion of GC
fluctuates in a circadian and stress-related fashion.
INTRODUCTION
Glucocorticoids (GCs) are peripheral effectors of circadian and
stress-related homeostatic functions fundamental for survival
throughout vertebrate life span (Chrousos, 2009; Nader et al.,
2010). They are widely used to combat inflammatory and allergic
disorders and their therapeutic effects have been mainly
ascribed to their capacity to suppress the production of proin-
flammatory cytokines (Rhen and Cidlowski, 2005). GCs act by
binding to the GC receptor (GR), a member of the nuclear
receptor (NR) superfamily. In absence of GCs, GR is maintained
in the cytoplasm by molecular chaperones. Binding of GCs
generates a conformational switch in the GR ligand binding
domain (LBD) which affects GR interactions with chaperones
and facilitates nuclear translocation (Ricketson et al., 2007).
Once in the nucleus, GR binds to GC response elements224 Cell 145, 224–241, April 15, 2011 ª2011 Elsevier Inc.(GREs) and regulates transcription of target genes. ‘‘Simple’’
GREs belong to a family of imperfect palindromes consisting of
two inverted hexameric half-site motifs separated by three
base pairs (bp) (Meijsing et al., 2009). Such ‘‘simple’’ (+)GRE
confer transcriptional transactivation to agonist-liganded GR
through association with coactivators (e.g., SRC1, TIF2/SRC2
and SRC3) (Lonard and O’Malley, 2007). ‘‘Composite’’ GREs
consist of DNA binding sites (DBS) for GR which, in association
with binding sites for other factors, can act synergistically to
mediate transactivation or transrepression. In a few of cases,
binding of GR to promoter regions has been implicated in GC-in-
duced transrepression, but no consensus sequence for ‘‘repres-
sing’’ negative GREs (nGREs) has emerged (Dostert and Heinzel,
2004). Remarkably, ‘‘tethering’’ GREs do not contain DBS for GR
per se, but instead contain binding sites for other DNA-bound
regulators, such as NFkB and AP1, that recruit GR (Karin,
1998; Kassel and Herrlich, 2007). Thus, tethering GREs confer
‘‘indirect’’ transrepression to agonist liganded GR.
Atopic dermatitis (AD) is an inflammatory skin disease that
exhibits a high prevalence (Bieber, 2008). We recently developed
mouse models which closely mimic human AD (Li et al., 2005,
2006), and revealed that inductionof theThymicStromalLympho-
poietin (TSLP) cytokine in epidermal keratinocytes is necessary
and sufficient to trigger a human AD-like syndrome. As topical
GCs are important tools for AD treatment, we wondered whether
their effect could result fromTSLP repression.We report that GCs
transcriptionally repress TSLP expression in AD mouse models,
and demonstrate that this repression is mediated through direct
binding ofGR to a ‘‘simple’’ nGRE,whichbelongs to a novel family
of evolutionary-conservedcis-actingnegative responseelements
(IR nGREs) found in numerous GC-repressed genes.RESULTS
Glucocorticoid-Induced GR-Mediated Transcriptional
Repression of TSLP Expression
The GC agonist fluocinolone acetonide (FA) was applied to ears
of mice concomitantly treated with the ‘‘low-calcemic’’ Vitamin
D3 (VitD3) analog MC903 (Calcipotriol; hereafter called MC) to
trigger TSLP expression (Li et al., 2006). In wild-type (WT) mice,
FA application inhibited basal TSLP RNA level by 50%, which
interestingly could be relieved by coapplication of the GC antag-
onist RU486 (mifepristone, hereafter named RU), while MC-
induced increase of TSLP RNA, which was fully blocked by FA,
was also restored by RU cotreatment (Figure 1A). Similarly, the
retinoic acid (RA)-induced increase of TSLP transcripts
(Li et al., 2006)wasblockedbyFAand restoredbyRU (FigureS1A
available online). As expected, the expression of the GC-induc-
ible GPX3 (glutathione peroxidase 3) gene which harbours a (+)
GRE (Tuckermann et al., 1999) was enhanced by FA (Figure 1A)
and inhibited by RU cotreatment, while FA or RU had no effect on
MC-dependent expression of the CYP24A1 gene (a VitD3 target)
(Figure 1A). Inhibition of TSLP expression by FA was not depen-
dent on its induction by MC or RA, as a 3-day FA application to
ears of RXRabep/ or VDR/RARagep/ mice (selectively lack-
ing in epidermal keratinocytes both RXRa and b, or VDR and
both RARa and RARg, respectively) which express high levels
of TSLP in epidermal keratinocytes in the absence of MC or RA
treatment (Li et al., 2005 and unpublished data) reduced TSLP
RNA by 70% (Figure 1B, left panel, and data not shown).
The GR involvement in FA-induced inhibition of MC-induced
TSLP expression in keratinocytes was demonstrated using adult
mice in which GR was selectively ablated in keratinocytes
(GRep/ mice). Although the basal TSLP level was similar in
vehicle-treated WT and GRep/ mice, FA blocked MC-induced
TSLP expression in WT, but not in GRep/mice (Figure 1B, right
panel). MC treatment was more efficient in GRep/ than in WT
mice, indicating that endogenous GCs may partially inhibit
MC-induced TSLP expression in WT epidermis. TSLP expres-
sion was similarly repressed by FA and restored by RU in mouse
intestinal epithelium (Figure S1B) and in human lung epithelial
cells A549 (Figure S1C), whereas expression of the (+)GRE-con-
taining mouse GPX3 and human GILZ (Wang et al., 2004)
GC-induced genes was enhanced by FA and inhibited by RU.
Nuclear run-on assays demonstrated that GR-mediated FA
inhibition of TSLP expression was transcriptional (Figure 1C).
A Putative Negative GRE Is Located in the TSLP
Promoter Region
As neither NFkB nor AP1 are involved in TSLP induction byMC in
epidermis (unpublished data), its repression was unlikely to be
mediated by a tethering GRE. A bioinformatics analysis of
20 kb of DNA located upstream and downstream from the
mouse and human TSLP translation startsite (+1) did not reveal
any (+)GRE or known ‘‘composite’’ activating or repressing
GRE, but unveiled the presence of a palindromic sequence con-
sisting of two inverted repeated (IR) motifs separated by one bp
(called hereafter IR1 nGRE), in the upstream promoter region of
both mouse (m) and human (h) TSLP genes (Figure 1E). Re-
combinant human GR protein in electrophoretic mobility shift
(EMSA) and supershift assays with GR antibody showed that
this putative mTSLP IR1 nGRE and its human counterpart, as
well as the TAT (+)GRE (Meijsing et al., 2009), bound to the GR
protein (Figure 1D, left panel). These bindings were specific, as
shown by lack of GR binding to a mutant (+)GRE and to three
mTSLP IR1 nGRE mutants (Mut1, 2, and 3) (Figures 1E and 1D,
middle panel). Complexes formed between the recombinant
GR and either putative IR1 nGREs or (+)GRE similarly migrated.As GR binds (+)GREs as a dimer (Wrange et al., 1989), two GR
monomers may bind these putative nGREs. Competition bind-
ings between [32P]-labeled mTSLP IR1 nGRE probe and excess
cold (+)GRE probe, and vice-versa, indicated that GR has
a higher affinity for (+)GRE than for TSLP IR1 nGRE (Figure 1D,
right panel).
Binding ofAgonist-LigandedGR to thePutative TSLP IR1
nGRE Enables the Formation of a Repressing Complex
GC-induced binding of GR to TSLP IR1 nGRE, the generation of
a repressing complex, and its effect on the organization of the
TSLP promoter regions, were investigated in vivo by chromatin
immunoprecipitation (ChIP) with WT epidermis and intestinal
epithelium, as well as in vitro with cultured A549 cells. Four
regions of the TSLP promoter were analyzed: the proximal
promoter region (PP), the region containing the IR1 nGRE, and
those containing the DR3d VitD3 (VDRE) and the DR2b Retinoic
Acid (RARE) response elements (unpublished data) (Figure 1F
and Figure S1D). ChIP assays of epidermis revealed weak bind-
ings of GR, as well as of SMRT and NCoR corepressors (Lonard
and O’Malley, 2007) to the nGRE region, which were strongly
increased upon a 6hr topical FA treatment (Figure 1G). The
concomitant disappearance of both GR and SMRT/NCoR bind-
ings to the nGRE region in GRep/mutant mice (Figure 1G) indi-
cated that corepressor bindings were associated with that of
GR, which was confirmed by colocalization of GR and corepres-
sors, when shorter segments of the nGRE region were explored
(Figure S1E). Upon FA treatment, in the same cells, GR as well as
SRC2, SRC3 and Pol II but not SMRT and NCoR, were recruited
to theGPX3 (+)GRE region (Figure S1F). Moreover, binding of GR
to (+)GRE, was antagonized by RU, which on its own, did not
allow the binding of GR to GPX3 (+)GRE (Figure S1F).
SMRT and NCoR are known to recruit histone deacetylase
(HDACs) to repressing complexes. As for GR and corepressors,
HDAC2 and HDAC3 were weakly bound to the nGRE in vehicle-
treated epidermis, and FA strongly enhanced this recruitment
(Figure S1G), further supporting that GC-induced binding of
GR to TSLP IR1 nGRE generates a repressing complex. RU
topical treatment precluded FA-induced generation of this
repressing complex on nGRE, whereas application of MC (Fig-
ure 1G and Figure S1G) or retinoic acid (RA) (Figure S1H, upper
panels) had no effect.
We also used mouse intestinal epithelium, which revealed,
upon FA intraperitoneal injection, a strong binding of GR
together with SMRT and NCoR corepressors to the TSLP IR1
nGRE region. RU addition precluded the generation of this
FA-induced repressing complex, whereas VitD3 had no effect
(Figure S1I, upper panel). Similarly, FA addition to A549 cells re-
sulted in a stronger binding of GR together with SMRT and NCoR
to the nGRE region (which was suppressed by RU, Figure S1J),
whereas it induced binding of an activating complex to the GILZ
gene (+)GRE (Figure S1K).
To demonstrate that SMRT and NCoR are instrumental in GC-
induced IR1 nGRE-mediated TSLP repression, we knocked-
downtheir expression inA549cellsby60%and80%, respectively,
with selective siRNA (Figure 1H). Upon single siRNA treatment,
ChIP assays showed a marked decrease in SMRT binding and
complete disappearance of NCoR binding to TSLP nGRE, whileCell 145, 224–241, April 15, 2011 ª2011 Elsevier Inc. 225
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Figure 1. Glucocorticoid-Induced Inhibition of TSLP Transcription Is Mediated through GR and Corepressors Binding to a Negative GRE
(A) Q-RT-PCR (Quantitative-RT-PCR) of TSLP, Cyp24A1 and GPX3 RNA from WT ear epidermis topically treated for 6 hr.
(B) TSLP Q-RT-PCR from RXRabep/ andWT ear epidermis FA-treated twice a day for 3 days (left panel). TSLP Q-RT-PCR from GRep/ andWT ear epidermis
treated for 6 hr (right panel).
(C) Nuclear run-on assays using WT dorsal epidermis treated as indicated. Upper panels: autoradiograms of labeled transcripts hybridized with TSLP, b actin or
pSK+ vector DNA. Lower panel: ethidium bromide (etbr) staining.
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no SMRT and NCoR binding could be detected upon siSMRT and
siNCoR RNAs cotreatment (Figure 1I). Dex-induced TSLP repres-
sion was prevented by concomitant knockdowns of SMRT and
NCoR, but not significantly affected by their single knockdown,
thus demonstrating that SMRT and NCoR are instrumental in
GC-induced IR1 nGRE-mediated repression, and that these two
corepressors can be functionally redundant. Interestingly, the
ChIP data suggest that GR is less efficiently bound to the IR1
nGRE in the absence of the two corepressors (Figure 1I). Note
that SMRT and NCoR knockdowns (on their own or together) did
not affect GR expression and Dex-induced transactivation of the
(+)GRE GILZ gene (Figure 1H).
Generation of a Repressing Complex on the TSLP IR1
nGREPrecludes the Formation of an ActivatingComplex
on VDRE, RARE, and Proximal Promoter Regions
In the absence of an agonist ligand, a repressing complex con-
taining VDR and SMRT was bound to TSLP DR3d VDRE
in epidermal keratinocytes, whereas it was replaced by
a VDR-SRC2/SRC3-Pol II activating complex upon MC topical
treatment (Figure 1G and unpublished results). Upon MC and
FA cotreatment, VDR association with the VDRE was not in-
hibited,whereas those of SRC2, SRC3, andPol II were drastically
reduced, and an association of SMRTwas observed (Figure 1G).
No association of GR to DR3d VDRE was detected, but these
latter changes are clearly related to binding of FA to GR, as RU
cotreatment (MC+FA+RU) restored theactivation bindingpattern
observed upon treatment with MC alone (Figure 1G). No GR
binding to the PP region could be detected upon FA treatment.
However, this treatment precluded VDR, SRC2, SRC3 and Pol
II bindings induced by MC treatment, and a RU cotreatment
(MC+FA+RU) reversed the effect of FA, indicating an involvement
of FA-liganded GR in preventing the association of VDR, SRC2/
SRC3 and Pol II with the PP region (Figure 1G, lower panels).
Similarly, the generation of a repressing complex on IR1 nGRE
precluded the formation of an activating complex on DR2b
RARE and the PP regions (Figure S1H). Note that, in contrast to
the DR3d VDRE complex, the DR2b RARE complex contains
SRC2 only.
In keeping with the above data, in intestinal epithelium, the
generation of a repressing complex on TSLP IR1 nGRE also(D) Left panels: EMSAwith recombinant humanGRprotein, andGR antibody (ab) s
point to the position of shifted [32P]- GREs in absence and presence of GR ab, re
either cold (+)GREc and [32P]- TSLP nGRE probes or cold TSLP nGREc and [32P]-
cold probe.
(E) Comparison of mouse (m) and human (h) TSLP nGRE sequences with that of TA
letters. N, any base. Mutated residues are in smaller font size.
(F) mTSLP promoter region. +1 is the ‘‘A’’ base of the translation initiation codon
Boxes represent promoter elements with their coordinates. Coordinates of DNA
(G) ChIP assays using dorsal skin fromWT and GRep/mice treated as indicated
antibodies. Control is rabbit IgG. 10% input indicates the signal obtained after PC
for each immunoprecipitation with a given antibody.
(H) Q-RT-PCR of SMRT, NCoR, GR, GILZ and TSLP transcripts from siSMRT an
(I) ChIP assays on Dex-treated A549 cells transfectedwith siSMRT and/or siNCoR
TSLP IR1 nGRE region.
(J) Chromosome conformation capture (3C) assays usingWT epidermis. Upper, m
and nGRE regions, and VDRE and PP regions, respectively.
Values are mean ± SEM.
See also Figure S1, Figure S7, Table S5, and Table S6.precluded formation of a VitD3-induced activating complex on
DR3d VDRE and the PP regions (Figure S1I, middle panels).
GC-Induced Formation of a Repressing Complex
on the TSLP IR1 nGRE Precludes Interaction between
VDRE and PP Regions
That, in presence of MC, the same activating complexes (VDR,
SRC2/SRC3 and Pol II) were associated with DR3d VDRE and
PP regions indicated that these two regions could be in close
apposition through chromatin looping. We therefore performed
Chromosome Conformation Capture (3C) assays on epidermal
chromatin of mice topically treated with vehicle, FA, MC,
MC+FA, RU, and MC+FA+RU. Cross-linked chromatin was di-
gested with Nla III restriction enzyme to separate DR3d, nGRE
and PP regions (Figure 1F), which were then ligated to reveal
possible interactions between PP and DR3d VDRE or nGRE
regions (Figure 1J). No interaction between nGRE and PP region,
nor between nGRE and VDRE, could be detected upon FA or RU
treatment, whereas an interaction was observed upon MC treat-
ment between DR3d VDRE and PP regions, which was
precluded by FA cotreatment (MC+FA), and restored upon RU
addition (MC+FA+RU) (Figure 1J). Interactions between DR3d
VDRE and PP regions were similarly revealed upon Alu I diges-
tion (Figures S1L and S1M). Thus, the TSLP IR1 nGRE which is
located 1.3 kb upstream from the PP region could act as
a silencer element precluding the formation of a chromatin
loop between the PP and the VDRE enhancer region located
7.3 kb upstream.
The Repressing Activity of the TSLP nGRE Tolerates
Changes in Spacing and/or Sequence of Its Repeated
Motifs
To investigate whether additional DNA elements could be
required to generate a repressing activity, we inserted the
TSLP IR1 nGRE upstream of an enhancerless SV40 early
promoter located 50 to the luciferase coding sequence of
pGL3 vector (Figure 2A). A VDRE separated from the IR1
nGRE by a 314bp-long DNA segment devoid of any known
transregulator binding site (not shown) was inserted to generate
a luciferase-expressing reporter plasmid (pGL3 vector 1), which
was transfected into A549 cells, followed by addition of VitD3upershift assays, using [32P] 50-labeled probes (panel E). Arrow and arrowhead
spectively. Right panel: Competition EMSA and GR ab supershift assays using
(+)GRE probes, as indicated. 103, 253, and 503 refers to foldmolar excess of
T (+) GRE. Palindromes are underlined. Conserved bases in nGREs are in bold
(ATG). A to E are Nla III-digested DNA fragments. 1 to 6 denotes Nla III sites.
segments (regions) PCR-amplified in ChIP assays are indicated.
. Amplified DNA regions are on the right side. IP antibody: immunoprecipitating
R amplification of the relevant DNA region contained in 10% of chromatin used
d/or siNCoR RNA-transfected A549 cells, treated as indicated.
RNA, (as indicated), to detect the binding of GR and corepressors to the human
iddle and lower panels reveal interaction between nGRE and PP regions, VDRE
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Figure 2. The TSLP nGRE Is Not a Composite Element, but Its Activity Is Affected by Changes in Spacing and/or Sequence of Its Inverted
Repeated Motifs
(A) pGL3 luciferase reporter plasmids (see Extended Experimental Procedures).
(B) Luciferase assays of A549 cells transfected with pGL3 vector 1 derivatives, and treated with FA and/or vitD3 (VD3).
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and/or FA. FA addition did not affect luciferase expression in
absence of IR1 nGRE, whereas its presence resulted in
decreased expression (which could be prevented by RU addi-
tion) of basal and VDRE-mediated VitD3-induced transcription
(Figures 2A and 2B). As expected, FA-induced increase in lucif-
erase expression was observed when IR1 nGRE was replaced
by a (+)GRE. The TSLP IR1 nGRE exhibited a similar FA-induc-
ible repressing activity when embedded in 413 bp of its natural
environment within the reporter pGL3 vector 2 (Figures 2A and
2C). Thus, on its own, TSLP IR1 nGRE is sufficient to mediate
a FA-inducible repressing activity, which resulted from the
generation of a repressing complex containing the SMRT core-
pressor and GR, as shown by ChIP assay (Figures 2D). Replac-
ing, in the reporter, IR1 nGRE by a mutant to which recombi-
nant GR does not bind (IR1 nGRE mut1, Figures 1D and 1E)
resulted in no GR binding (Figures 2D and 2E) and no FA-induc-
ible repressing activity (Figure 2C and F), thus supporting the
conclusion that GR binds directly to TSLP nGRE in cultured
cells. In keeping with our above data in vivo, the addition of
RU to FA prevented the formation of the repressing complex
(Figure 2D), and RU on its own was unable to induce GR
binding to TSLP IR1 nGRE inserted in the pGL3 vector 1
(Figures 2D and 2E).
To investigate whether the 1 bp spacer between the inverted
repeated motifs of TSLP IR1 nGRE was critical for its repressing
function, pGL3-based luciferase plasmids containing the VDRE
and TSLP nGRE motifs spaced by 0 to 5 bases (IR0 to IR5
nGREs) were transfected into A549 cells (Figures 2E and 2F,
and data not shown). ChIP assays showed that, upon FA addi-
tion, GR similarly bound IR1 and IR2 nGREs, whereas its binding
was less efficient on IR0 nGRE, and not detectable on IR3, IR4,
and IR5 nGREs (Figure 2E). Accordingly, upon FA addition, the
decrease in basal and VitD3-induced luciferase activity was
stronger for IR1 and IR2 than for IR0 nGRE, whereas no signifi-
cant change could be detected for IR3, IR4 and IR5 nGREs (Fig-
ure 2F, and data not shown).
pGL3-based luciferase plasmids containing VDRE and TSLP
IR1 nGREs (Figure 2A), in which individual bases had been
changed one by one, were used to study whether non-canon-
ical IR1 nGREs could function as efficient nGREs (Figure 2G).
With one exception, at least a one base pair change was
‘‘tolerable’’ at any position of the TSLP IR1 nGRE and did
not impair its activity in vitro, suggesting that GR bound to
‘‘degenerate’’ IR1 elements might also mediate GC-induced
direct repression in vivo (see below). A similar analysis carried
out with plasmids containing IR2 nGREs showed that a one
base pair change was tolerable at any position of IR2 nGRE
(Figure S2).(C) Luciferase assays of FA-treated A459 cells transfected with TSLP nGRE 413
a pGL3 SV40 enhancer vector1 (see panel [A]) containing the TSLP IR1 nGRE (s
(D) ChIP analysis of GR and SMRT recruitment to IR1 nGRE or IR1 nGRE mutant1
(E) ChIP analysis of GR binding to IR0, IR1, IR2, IR3, IR4, IR5 nGRE and (+) GRE pre
(F) Luciferase assay showing the effect of IR nGRE spacer length (as indicated) o
(G) Functionality of variousmutant IR1 nGRE elements bearing a 1 bp change. Righ
Circled numbers: intolerable mutations. Bigger letters: sequence of canonical IR
Values are mean ± SEM.
See also Figure S2 and Table S5.Mouse Genes that Contain IR0, IR1, and IR2 nGREs
Conserved in Their Human Orthologs Are Repressed
upon GC Agonist Treatment In Vivo
Bioinformatics analyses of mouse and human genomes revealed
thousands of genes containing IR elements made up of inverted
repeated motifs identical to those of TSLP (CTCC and GGAGA)
with either no (IR0), 1 (IR1) or 2 (IR2) bp spacers (Table 1A). A
comparison of mouse and human orthologs indicated conserva-
tions of such IR elements (51 IR0, 379 IR1, and 566 IR2; Table 1A
and Table S1). Within these ortholog gene families, we randomly
chose 35 IR0, 50 IR1, and 50 IR2 nGRE-containing mouse genes
(Extended Experimental Procedures) to investigate whether (1)
they were expressed in epidermis, intestinal epithelium and liver,
(2) their expression was inhibited by the GC agonist Dexametha-
sone (Dex), (3) this inhibition could be relieved byRU486 coadmin-
istration, and also if it could becorrelatedwithGRand corepressor
binding to their putative IR nGREs. These genes were found to be
expressed in one, two or all three tissues, and when expressed,
were cell specifically repressed or not repressed (Table 1B).
For nine of the above ‘‘IR1’’ genes, we tested the repressing
activity of their putative IR1 nGREs in vitro using the luciferase
assay (Figure 2A and Figure 3D). In all cases, and irrespective of
the tissue pattern of GC-induced repression, these putative IR1
nGREs ‘‘repressed’’ luciferase activity (Figure 3D), indicating that
these IR1 nGREs elements are bona fide IR1 nGREs. Importantly,
upon GC treatment in vivo, there was a tight correlation between
repression of a given gene in a given tissue (and its relief by RU
coadministration), and GR and corepressor association with the
IR1 nGRE of that gene in that tissue (compare in Figures 3E–3G
with Figures 3A–3C, respectively). In contrast there was no GR
and corepressor association with the IR1 element of BMP3 gene
which is not ‘‘repressed’’ in either tissue (Figures 3E–3G). These
data indicate that, not only could the tissue-specific expression
of genes, which potentially can be negatively controlled by GCs,
be subjected to epigenetic control, but also that their GC-repres-
sion itself could also be epigenetically controlled, which suggests
that additional mechanisms operate in the negative control of
gene expression mediated by IR nGREs (e.g., USF1 in Figures
3A–3G).Note thatdependingon thegeneand the timeof exposure
of the animal to FA or Dex (6 and 18 hr), the corepressor compo-
nents of the repressing complex may change (Figures 3E and 3F).
The ‘‘IR0’’ genes (Figure S3A–S3C, and Table 1B) and ‘‘IR2’’
genes (Figures S4A–S4C, and Table 1B) were also cell specifi-
cally or noncell specifically expressed and repressed in the three
tissues. We tested the GC-induced repressing potential of puta-
tive IR nGREs of some of the selected ‘‘IR0’’ and ‘‘IR2’’ genes
using the luciferase assay, and found that they exhibited a re-
pressing activity, irrespective of their activity in vivo (Figure S3Dbp pGL3 vector 2, TSLP nGRE mutant1 (Figure 1E) 413 bp pGL3 vector 2, or
equence in panel [F]).
of pGL3 IR1 nGRE vector 1 transfected in A549 cells treated with FA and RU.
sent in pGL3 vector 1, following FA andRU treatment of transfected A459 cells.
n repressing activity.
t panel: sequences of the canonical IR1 nGRE and its variants are listed 1 to 28.
nGRE; smaller letters: tolerable base changes.
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Table 1.
RNA isolated from 18 hr- Dex-treatedWTmice epidermis, intestinal epithelium, and liver was analyzed by Q-RT-PCR. Genes, for which no signal could
be detected in tissue samples from vehicle treatedmice after 60 cycles of amplification, were considered to be not expressed in that tissue. (+) indicates
that the gene was expressed in that tissue while ‘‘repressed’’ denotes statistically (p < 0.05) significant decrease in transcript levels after Dex treatment.
For individual data, see Figures 3A, 3B, 3C, (IR1 nGRE), Figures S3A, S3B, S3C (IR0 nGRE), and Figures S4A, S4B, and S4C (IR2 nGRE).and Figure S4D). Upon Dex treatment, a decrease in gene
expression in a given tissue always correlated with GR and core-
pressor association with the IR0 or IR2 element in that tissue
(Figures S3E and S3F and Figures S4E and S4F), and in all cases
the GC-induced repression was relieved by coadministration of
RU. We conclude that, as expected from our in vitro luciferase
assays, not only IR1, but also IR0 and IR2 nGREs can efficiently230 Cell 145, 224–241, April 15, 2011 ª2011 Elsevier Inc.mediate the cis-acting GC agonist-induced repressing activity of
the GR, in vivo.
IR nGREs of Mouse and Human Orthologs May Differ
by a Tolerable One-Base-Pair Mutation
As Keratin 5 (K5), known to be downregulated by GCs (Ramot
et al., 2009, and Figure 3H showing that Dex treatment-induced
decrease in epidermal K5 transcript levels can be prevented by
RUcoadministration), was not present in the list of human/mouse
orthologs that contain a canonical nGRE (Table S1), we looked
whether this absence could reflect the presence of a canonical
IR1 nGRE in human K5, while a tolerable change would exist in
its mouse ortholog, or vice-versa. We found one canonical IR1
nGRE inhumanK5gene and3putative nGREs in itsmouseortho-
log, each of them exhibiting one tolerable change in vitro (Fig-
ure S5A). Only one of them (mK5 IR1 nGRE2) allowed formation
of a GR-SMRT repressing complex in epidermis of Dex-treated
mice (Figure 3I), suggesting that not all in vitro tolerable IR1
nGRE variants are functional in a given tissue.
Similarly, we looked at insulin (ins) and insulin receptor (insr)
genes, as their expression was reported to be downregulated
by GCs (Delaunay et al., 1997; see also Figure 3H, showing
that these downregulations - in pancreas for insulin, and in liver
for insulin receptor - can be prevented by RU cotreatment). A
canonical IR1 nGRE was found in the human insulin receptor
gene (hinsr IR1 nGRE), and two IR1 nGREs, each bearing one
tolerable change, were present in the mouse (Figure S5B).
Upon Dex treatment, functional GR-SMRT/NCoR repressing
complexes were assembled on both mouse insulin receptor
IR1 nGRE variants (minsr IR1 nGRE1 and 2 in Figure 3I). Remark-
ably, in addition to a canonical IR2 nGRE in both human and
mouse insulin genes, a tolerable IR1 nGRE variant was present
in mouse insulin gene, while a canonical IR1 nGRE was present
in the human gene (Figure S5B). Interestingly, in vitro studies
suggested 20 years ago that this latter human element could
act as a negative GRE (Boam et al., 1990; Goodman et al.,
1996). Upon Dex treatment, repressing complexes were bound,
in mouse pancreas, to both the IR1 nGRE variants and the IR2
nGRE of the insulin gene. However, in the absence of Dex treat-
ment, this complex (whose formation could be prevented by RU
administration; data not shown) could be detected (albeit fainter)
on the IR1 nGRE variant, but not on the IR2 nGRE (Figure 3I), sug-
gesting that the affinity of the latter for liganded GR could be
lower.
We also looked at Reverba, as its downregulation by GCs was
previously reported (Duez and Staels, 2008, and Refs therein). A
canonical IR1 nGRE was found in mouse, but not in human
Reverba gene, which contains 3 IR1 nGREs each bearing one
tolerable variant (Figure S5C). Note that, in the mouse, this
gene also contains an IR1 nGRE variant (mReverba IR1
nGRE2), that is identical to one of the human nGRE variants
(hReverba IR1 nGRE2 in Figure S5C), and appears to be as func-
tional as the mouse canonical IR1 nGRE1, as judged from ChIP
assays with liver extracts (Figure 3I).
Genes Downregulated by Glucocorticoids in Human
A549 Cells Contain Functional IR nGREs
DNA microarray and ChIP scanning (Wang et al., 2004), and
RNA-seq (Reddy et al., 2009) searches for GC target genes
have revealed the existence of a number of genes, the expres-
sion of which is downregulated by GCs in A549 cells. In the first
study, three out of 21 genes have been ChIP-scanned for GR
binding. Upon Dex-treatment of A549 cells, we found that two
of these human genes [BHLHB2 which is the ortholog of the
STRA13 mouse gene (Table 1B), and GEM] contain IR nGREs(Table S2), on which assembly of repressing complexes could
be prevented by excess RU cotreatment (Figures S6A and
S6B). In Reddy et al. (2009) RNA-seq study, out of 85 GC-down-
regulated genes, 31 contain IR nGREs (Table S2). We analyzed
15 of them by Q-RT-PCR and ChIP assay after treatment with
Dex or Dex + RU. All of them exhibited a Dex-induced downre-
gulation, which was reversed by excess RU (Figure S6A). For
all of these 15 genes, a repressing complex, of which the forma-
tion upon Dex treatment of A549 cells was inhibited by excess
RU,was associatedwith at least one of their nGREs (Figure S6B).
Interestingly, it appears that SMRT or NCoR can be selectively
bound to the IR nGRE of a given gene, whereas both SMRT
and NCoR are bound to the TSLP IR1 nGRE (Figure S1J). More-
over, as previously seen for TSLP (Figure 1 H and I), siRNA
knockdowns of SMRT and NCoR in A549 cells demonstrate
that these corepressors were instrumental in Dex-induced IR
nGRE-mediated transrepression (Figures S7A and S7B).
Furthermore, these knockdowns reveal that, even though
binding of these corepressors exhibit gene specificity, they can
be redundant for their repression function when one of them is
knocked-down. Note that in several cases, binding of GR to
the IR nGRE was altered when the two corepressors were
knocked-down (Figure S7B).
Reddy et al. (2009) also reported a whole-genome ChIP-seq
analysis of GRDBS in Dex-treated A549 cells. Among all of these
GR DBS (4392), we selected those containing IR1 or IR2 nGREs
(allowing for 1 tolerable change) located within known genes and
their promoter regions (see Extended Experimental Procedures;
these 313 genes are listed in Table S4). Five of them were
randomly chosen among those the transcription of which was
decreased in A549 cells by Dex treatment for 18 hr, and rescued
by RU cotreatment (Figure S6C). For all 5 genes, ChIP assays
with vehicle-treated A549 cells showed the presence of Pol II
on the promoter proximal (PP) region, its disappearance upon
Dex treatment, and reappearance upon RU addition.
Conversely, GR and NCoR were bound to IR nGREs in the pres-
ence of Dex, but not in vehicle or Dex+RU-treated cells, thus
demonstrating that the expression of these genes is transcrip-
tionally repressed through GC-induced IR nGRE-mediated
direct transrepression (Figure S6D).
Differential Effects of the GRdim Mutation and RU486
Treatment on GC-Induced Tethered and IR nGRE-
Mediated Transrepressions
The GRdim mutation does not affect GC-induced NFkB and
AP1-mediated ‘‘tethered’’ transrepression, whereas it impairs
(+)GRE transactivation (Tuckermann et al., 1999). In contrast,
we found that Dex-induced IR nGRE-mediated gene repression
was abolished by this mutation (Figure 4A, and data not
shown). Expression of ‘‘IR0 nGRE’’ CCND1, ‘‘IR1 nGRE’’
PRKCB and ‘‘IR2 nGRE’’ FSTL1 genes, was repressed by
Dex treatment in WT epidermis, but not in GRdim mutant.
Note that epidermis was treated as indicated with TPA, to acti-
vate NFkB and AP1 factors. As expected, the repression of the
Cox2 gene that contains NFkB and AP1 binding sites, was not
impaired in mutant epidermis, while the (+)GRE-containing
GPX3 gene was not GC-induced (Figure 4A). Accordingly,
ChIP assays showed that Dex-induced repressing complexesCell 145, 224–241, April 15, 2011 ª2011 Elsevier Inc. 231
A Epidermis
VEHICLE DEX RU DEX + RU
F
tro
l
RT  in
pu
t
tro
l
RT in
pu
t
t ro
l
RT in
pu
tnGRE
ChIP
primers
IP
antibody
IP
antibody
IP
antibody
0
1
3
0.3
R
el
at
iv
e 
R
N
A
 le
ve
l
2
C
on
t
N
C
O
S
M
R
T
10
%
G
R
C
on
t
N
C
O
R
S
M
R
T
10
%
 
G
R
C
on
t
N
C
O
R
S
M
R
T
10
%
 
G
R
nt
es
tin
al
 e
pi
th
el
iu
m
BCL2L1
PRKCB
JUND
GBA2
RDH11
BTG2
NKRF
BMP3
FBLN2
C
on
tro
l
N
C
O
R
S
M
R
T 
G
R
C
on
tro
l
N
C
O
R
S
M
R
T 
0%
 in
pu
t
G
R
nGRE
ChIP
primers
IP
antibody
IP
antibody
1
2
Intestinal Epithelium
ve
 R
N
A
 le
ve
l
B
VEHICLE DEX RU DEX + RU
G
InTNFR SF19
TSLP
USF1
vehicle dex 6hr. dex 18hr.Treatment:
BCL2L1
C NS G C NS 1G
Li
ve
r
3
C
Liver
el
VEHICLE DEX RU DEX + RU
0R
el
at
iv
BMP3
FBLN2
HSD11B2
NKRF
PRKCB
USF1
vehicle dex 6hr.Treatment:
0
1
2
R
el
at
iv
e 
R
N
A
 le
ve
D
A
H
I
IP IP
R
el
at
iv
e 
R
N
A
le
ve
l
0
1
2
Dex:  -
RU:  -
+ +-
+ +-
+ +-
+ +-
-
-
K5           ins          insr Reverbα MC2R     MRAP
(pancreas)  (liver)
+ +-
+ +-
-
-
+ +-
+ +-
-
-
+ +-
+ +-
-
-
+ +-
+ +-
-
-
(epidermis) (liver) (adrenal) (adrenal)
R
el
at
iv
e 
Li
gh
t
U
ni
ts
 (
10
00
)
×
1.0
0.5
VD3:
FA: +
JUND HSD
11b2
SOCS3 PRKCB USF1
P=
.0
3
P=
.0
1
P=
.0
24
P=
.0
2
P=
.0
06
BCL2L1 NKRF
GL3 VDRE/ GRE
P=
.0
04
P=
.0
06
P=
.0
12
P=
.0
25
-
-
- ++
+-
-
-
- ++
+-+
-
-
- ++
+-+
-
-
- ++
+-+
-
-
- ++
+-+
-
-
- ++
+-+
-
-
- ++
+-+
-
-
- ++
+-+
-
-
- ++
+-+
CDK9BMP3
antibody
C
on
tro
l
10
%
in
pu
t
G
R
S
M
R
T
N
C
O
R
10
%
 in
pu
tantibody
mK5 IR1 nGRE1
mK5 IR1 nGRE2
mK5 IR1 nGRE3
ChIP
Primers
ep
id
er
m
is
pa
nc
re
as mins IR1 nGRE
mins IR2 nGRE
C
on
tro
l
G
R
S
M
R
T
N
C
O
R
p n
C
on
tro
l
N
C
O
R
S
M
R
T 
10
%
 in
pu
t
G
R
CYP26A1
C
on
tro
l
N
C
O
R
S
M
R
T 
10
%
 in
pu
t
G
R
C
on
tro
l
N
C
O
R
S
M
R
T 
10
%
 in
pu
t
G
R
C
on
tro
l
N
C
O
R
S
M
R
T 
10
%
 in
pu
t
G
R
C
on
tro
l
N
C
O
R
S
M
R
T 
10
%
 in
pu
t
G
R
nGRE
ChIP
primers
IP
antibody
E IP
antibody
IP
antibody
IP
antibody
IP
antibody
BCL2L1
K14
HSD11B2
s
BMP3
Vehicle Dex
minsr IR1 nGRE1
minsr IR1 nGRE2
mReverbα IR1 nGRE1
mReverbα IR1 nGRE2
Li
ve
r
p
TNFR SF19
TSLP
PRKCB
USF1
FA 6hr. dex 6hr. dex 18hr.FA 18hr.Treatment: vehicle
E
pi
de
rm
is
NKRF
Figure 3. Glucocorticoid-Induced Repression of Mouse Genes that Contain IR1 nGREs Conserved in Mouse and Human Orthologs Is
Relieved by RU486 Coadministration
(A) Q-RT-PCR for transcripts of IR1 nGRE-containing genes (Table 1B) in WT epidermis topically-treated with Dex and/or RU486 (RU) for 18 hr.
(B) As under (A), but using intestinal epithelium of intraperitoneally (IP)-injected WT mice.
(C) As under (B), but using WT liver.
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were formed on IR nGREs of CCND1, PRKCB and FSTL1 genes
of WT but not of GRdim mice (Figure 4B), while no activating
complex was formed on the GPX3 (+)GRE gene in Dex-treated
epidermis of GRdim mutants (Figure 4C), and repressing
complexes were assembled, upon epidermis Dex treatment,
on the Cox2 NFkB/AP1-containing region in both WT and dim
mutants (Figure 4D).
Importantly, the effect of Dex treatment was reverted by
excess RU cotreatment in the case of IR nGRE-mediated trans-
repression (Figures 4A and 4B), whereas RU had little effect on
NFkB/AP1-mediated tethered transrepression (Figures 4A and
4D). Similar results concerning the differential RU effects were
obtained when NFkB and AP1 factors were activated in MLE12
mouse cells by addition of IL-1b, instead of TPA treatment
(Figures 4E–4G; in panels 4E and 4F, the USF1 gene was
analyzed instead of the PRKCB gene in panels 4A and 4B,
because the latter is not expressed in MLE12 cells). Note that
no NFkB or AP1 are bound to the IR nGRE regions of CCND1,
PRKCB, USF1, and FSTL1 genes (Figures 4B and 4F).Failure of Dissociated GCs to Prevent Undesirable Side
Effects of Corticoid Therapy Could Be Due to IR nGREs-
Mediated Transrepression
The anti-inflammatory and immune-suppressant properties of
GCs represent the central target of pharmacological GC
therapy. It is thought that debilitating effects of GC treatment
are due to (+)GRE-mediated gene transactivation, while GC
beneficial anti-inflammatory effects have been mostly ascribed
to tethered transrepression (Karin, 1998; Kassel and Herrlich,
2007). This led to a search for ‘‘dissociated’’ GR ligands which
would preferentially induce tethered transrepression. Such
a ligand, RU24858, was found to exhibit the expected dissoci-
ated profile in vitro (Vayssie`re et al., 1997). However, upon
RU24858 administration in vivo, pathophysiological studies
failed to confirm this dissociation (Belvisi et al., 2001). Our
present results, led us to posit that GC-induced transcriptional
repression of IR nGRE-containing genes could contribute to
the GC undesirable effects.
IL-1b-‘‘activated’’ A549 cells transfected with pGL4- and
pGL3-based reporter plasmids were used to examine the
activities exhibited in vitro by RU24858 for (1) tethered transre-
pression (Figure 5A; NFkBluc and AP1luc plasmids), (2) (+)
GRE-mediated transactivation [Figure 2A; (+)GRE pGL3 lucif-
erase plasmid], and (3) IR0, IR1, or IR2 nGRE-mediated transre-
pression (VDRE/IR0, IR1, or IR2 nGRE pGL3 luciferase plasmids,(D) Luciferase assays on A549 cells transfected with pGL3 vector 1 derivative (Fig
for 6 hr with vehicle, VD3 and FA, as indicated.
(E) ChIP analysis of FA- and Dex- induced binding of GR and corepressors to IR
(F) ChIP analysis of Dex- induced binding to the IR1 nGRE regions of genes ana
(G) ChIP analysis of Dex- induced bindings to the IR1 nGRE regions of genes an
(H) Q-RT-PCR of gene transcripts, as indicated (see also Table 2A and Table S3)
Dex and/or RU, for 18 hr.
(I) ChIP analysis of epidermis, pancreas and liver showing binding of GR and cor
treated with vehicle or Dex (in the case of K5) or IP-injected with vehicle or Dex
Values are mean ± SEM.
See also Figure S3, Figure S4, Figure S5, Figure S6, Table S2, Table S4, and TaFigures 2A and 2F). As expected from its dissociated profile
in vitro, RU24858 was almost as efficient as Dex at repressing
IL-1b-induced activation of transcription by NFkB (Figure 5B,
left panel) and AP1 (Figure 5B, right panel). Accordingly,
RU24858 was as efficient as Dex at recruiting a repressing
complex tethered to NFkB bound to its cognate element in the
NFkBluc plasmid (Figure 5C). Most interestingly, RU24858 was
also as efficient as Dex at inducing repression mediated by
IR0, IR1 and IR2 nGREs in VDRE/IR0, IR1 and IR2 nGRE pGL3
luciferase plasmids (Figure 5D), as well as at recruiting GR and
SMRT to form repressing complexes on nGRE-containing
regions (Figure 5E). In contrast, RU24858wasmuch less efficient
than Dex at inducing transactivation of (+)GRE pGL3 luciferase
plasmid (Figure 5D).
We next investigated the ‘‘activity profile’’ of RU24858 in vivo.
Unlike Dex, a topical RU24858 treatment did not activate
GC-dependent expression of the (+)GRE-containing GPX3
gene in epidermis, nor of the GGT1 and ERP27 genes in liver
(Figure 5F), and did not induce assembly of an activating
complex on their (+)GRE (ChIP assays in Figure 5H, and data
not shown). In contrast, RU24858 was as efficient as Dex at
downregulating, through NFkB-mediated tethered transrepres-
sion, genes of which the skin expression was enhanced by
topical TPA treatment (Figure 5G). Most interestingly, and as
in vitro, RU24858 was also as efficient as Dex at inducing trans-
repression of IR0 (CCND1), IR1 (TSLP, CYP26A1, K14, PRKCB)
and IR2 (DPAGT1) nGRE-containing genes, through recruitment
of GR-SMRT/NCoR repressing complexes on nGRE regions
(Figures 5F and 5H).IR nGRE-Containing Genes Exert Physiological
Homeostatic Functions Related to Debilitating Effects
of Glucocorticoid Therapy
Long-term treatments with GCs generate numerous debilitating
effects (Table 2A, and references therein). An ontology search re-
vealed that the known or putative functions of almost 15% of IR
nGRE-containing ortholog genes could possibly be implicated in
physiological homeostatic processes leading to side-effects
upon GC therapy (Table S3). Moreover, there is evidence that
repression of expression of a number of these latter genes could
actually be instrumental to the generation of defects subsequent
to GC administration, either because their expression is known
to be decreased upon GC treatment, and/or because their
decreased expression is known to generate defects related to
those produced by GC-therapy (Table 2A; see also referencesure 2A) containing IR1 nGREs from genes (Table 1B) as indicated, were treated
1 nGRE regions of genes analyzed in panel (A).
lyzed in panel (B).
alyzed in panel (C).
, in WT mice topically-treated (epidermis) or IP-injected (for other tissues) with
epressors to the IR nGRE regions of indicated genes. WT mice were topically-
(in the case of ins, insr and Reverba) for 18 hr.
ble S5.
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(A) Q-RT-PCR of gene transcripts in WT and GRdim mutant mice treated as indicated for 6 hr.
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Values are mean ± SEM.
See also Table S5.in Table S3). Note, however, that many of the NFkB and AP1
binding site-containing genes that encode regulatory compo-
nents (e.g., cytokines) of the immune system, also contain IR
nGREs (Table 2B and Table S3), while genes encoding anti-234 Cell 145, 224–241, April 15, 2011 ª2011 Elsevier Inc.apoptotic proteins (Bcl2 and Bcl-XL), as well as mitogenic
proteins involved in cell cycle progression at the G1/S phase
(Cyclin D1 and CDK4) can also be GC-transrepressed via
IR nGREs (Table 2 and Table S3).
DISCUSSION
GC-Induced Direct Transrepression Is Mediated by
a Family of IR nGREs Present in Numerous Genes
We have discovered a widespread conserved family of ‘‘nega-
tive’’ palindromic GC-response elements (IR nGREs) that
mediate transrepression by direct binding of GC-agonist-li-
ganded GR which assembles a repressing complex through
association of SMRT/NCoR corepressors and HDACs.
GC-induced IR nGRE-mediated direct transrepression is distinct
from GC-induced tethered indirect transrepression, as: (1) teth-
ering GREs do not contain DNA binding sites for GR per se,
but instead binding sites for other DNA-bound transregulators
(e.g., NFkB and AP1) that recruit GR, (2) the GRdim mutation
that does not affect tethered transrepression, abolishes
IRnGRE-mediated direct transrepression, (3) cotreatment with
RU486 relieves GC-induced IRnGRE-mediated direct transre-
pression, whereas tethered transrepression is not or only slightly
affected, (4) IR nGREs appear to act as silencer elements, on
which the GC-induced assembly of a repressing complex
precludes the interaction between an enhancer and the proximal
promoter region.
Investigating in vitro whether the integrity of the TSLP nGRE in
which a 1 bp spacer separates the Inverted Repeatedmotifs (IR1
nGRE) is essential for its function, has shown that no (IR0 nGRE)
or a 2 bp (IR2 nGRE) spacer is ‘‘tolerable.’’ Moreover, one base
changes at any position of the ‘‘canonical’’ repeatedmotifs of the
TSLP IR1 nGRE and of its IR2 nGRE derivative is, with one
exception, functionally tolerable in vitro. Mouse and human
genomewide analyses revealed the presence of hundreds of
mouse and human ortholog genes containing conserved canon-
ical IR0, IR1 and IR2 nGREs (Tables 1A and 1B). In no case are
these nGREs located in the near vicinity (<100 bp) of binding
sites for regulatory factors (i.e., there is no evidence that IR
nGREs are composite sites), and most of them are conserved
throughout vertebrates (mammals, chicken and zebra fish, our
unpublished data). A number of ‘‘IR0,’’ ‘‘IR1,’’ and ‘‘IR2’’ nGRE-
containing genes expressed in mouse epidermis, intestinal
epithelial cells or liver, were analyzed for (1) repression by Dex-
treatment, (2) prevention of this repression by RU486 cotreat-
ment, (3) association of their IR nGREs with liganded-GR and
corepressors, and (4) repressing activity of their nGREs in vitro,
which taken all together represent the signature of IR nGRE-
mediated transrepression. This analysis demonstrates that IR0,
IR1, and IR2 nGRE-containing genes can be efficiently transre-
pressed by agonist-ligandedGRs bound to their nGREs together
with corepressors. Moreover, not only the tissue-specific
expression of these genes is epigenetically controlled but,
when expressed, their GC-induced transrepression is also
epigenetically controlled (Table 1B and Figure 3). Assuming
that the mouse/human genes that we have randomly selected
are representative, our data (Tables 1A and 1B) indicate that
the expression of approximately 600 mouse/human ortholog
genes could be negatively controlled through nGRE-mediated
transrepression in epidermis, intestinal epithelium and liver.
Therefore, provided the remaining 400 mouse/human ortholog
genes that contain canonical IR nGREs are expressed in other
tissues, it is likely that the expression of all (1000) of the ortho-log genes listed in Table S1 are negatively controlled in the
mouse by GC-induced IR nGRE-mediated transrepression.
Note, in this respect, that most of the IR nGRE-containing genes
present among the GC downregulated genes characterized in
the Reddy et al. (2009) RNA seq study of human A549 cells
treated with Dex (Table S2), are different from those identified
by us in epidermis, intestinal epithelial cells and liver (Table
1B). Similarly, only 7 out of the 313 human IR1 and IR2 nGRE-
containing genes identified by ChIP-seq analysis of GR DBS in
Dex-treated A549 cells (Reddy et al., 2009)(see Table S4) are
present among the 1000 human/mouse ortholog genes listed
in Table S1. In fact, the actual number of genes whose expres-
sion could be negatively controlled by GC-induced IR nGRE-
mediated transrepression might be much higher, as the exis-
tence of functionally tolerable single base changes in IR nGREs
of human and/or mouse ortholog genes could result in underes-
timating by several hundreds the actual number of genes con-
taining functional IR nGREs. In this respect, we note that most
of the IR nGREs present among the GC downregulated genes
characterized by Reddy et al. (2009) exhibit canonical repeated
motifs, whereas the nGREs of their mouse orthologs bear toler-
able single base changes, and therefore are not present in Table
S1 (data not shown).
Structural studies are obviously required to unveil the detailed
mechanism that underlies GC agonist-induced IRnGRE-medi-
ated direct transrepression. The role played by an agonistic
GC in this transrepression cannot be simply to ensure the trans-
location of the GR into the nucleus, as the GC antagonist RU486,
known to promote such a translocation, acts as an antagonist of
IR nGRE-mediated transrepression. Moreover, ChIP assays
in vivo (Figure 1 and Figure S1) and in vitro (Figure 2) show that
binding of a GR corepressor complex to IR nGREs requires the
presence of a glucocorticoid agonist which ‘‘normally’’ is known
to induce a GR conformational change that allows the formation
of a GR coactivator complex that binds to a (+)GRE (Figure S1F).
Whether the IR nGRE DNA binding site may possibly act as
a conformational ‘‘allosteric’’ effector of GR, enabling it to bind
corepressors in the presence of a GC-agonist, and to which
extent binding of the latters may strengthen the binding of the
GR to IR nGREs (see Figure 1I and Figure S7B), remains to be
seen.
Physiological and Pathophysiological Importance
of GC-Inducible Direct Transrepression by IR nGRE-
Containing Genes
GCs that act as end-effectors of the HPA (hypothalamus-pitui-
tary-adrenal) axis, are secreted by adrenal glands in a circadian
and stress-related manner. They influence the functions of virtu-
ally all organs and tissues throughout life span, and are essential
for maintenance of their homeostasis and important biological
activities, such as intermediary metabolism, immune and inflam-
matory reactions, as well as circadian clock and stress systems
(Chrousos, 2009; Nader et al., 2010). Our ontology search (Table
S3) has revealed that a number of IR nGRE-containing genes are
involved in such functions. We focus here on a few examples
illustrated in the present study.
Our data (Figures 3H and 3I, and Table 2A) unequivocally
demonstrate that GC-induced IR nGRE-mediated repression ofCell 145, 224–241, April 15, 2011 ª2011 Elsevier Inc. 235
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both the insulin precursor gene (in pancreas b cells) and insulin
receptor gene (in liver) are early stress-induced events. This
ensures that, upon occurrence of a stress, an elevation of blood
glucose level will rapidly follow the surge of GC secretion,
thereby providing the increased nutrition of brain, heart and skel-
etal muscles, required for the central coordination of stress
response (Chrousos, 2009). On the other hand, under conditions
of chronic stress, GC-induced IR nGRE-mediated repression of
the insulin receptor gene may cause insulin resistance and lead
to diabetes. Our study also reveals the existence of functional
IR1 nGREs in ACTH receptor (melacortin 2 receptor, MC2R)
gene, and ACTH receptor accessory protein (MRAP) gene (Fig-
ure 3H, Table 2A, and Table S3), thereby adding, at the adrenal
level, another step to the closed negative feedback loop that
resets the HPA axis by regulating the synthesis of secreted
GCs through GR-mediated repression of CRH and POMC
gene expression in hypothalamus and pituitary, respectively
(Dostert and Heinzel, 2004). We also found GC-induced IR
nGRE-mediated repression for the Reverba gene (Figures 3H
and 3I and Table 2A) and the RORa gene (Table 1B and Fig-
ure S4), which both intervene in the control of the circadian
timing system, and are likely to play an important role in commu-
nications of the molecular Clock and stress systems with inter-
mediary metabolism, which are fundamental for survival (Duez
and Staels, 2008; Nader et al., 2010; and references therein).
Importantly, it is known from previous studies that the expres-
sion of a number of genes is decreased upon GC therapy (Table
2Aand references therein), but the underlying pathophysiological
molecular mechanisms were often unknown. Our data demon-
strate that, upon GC therapy, decrease of keratins 5 and 14 in
skin, as well as those in Cyclin D1 and CDK4, are due to
GC-induced IR nGRE-mediated repression (Table 2A and Fig-
ure 3). Hsd11b2 is another important gene that is repressed by
IR1 nGRE-mediatedGC-treatment in both skin and colon tissues
(Figure 3A, and data not shown). The 11b-HSD2 enzyme (en-
coded in Hsd11b2 gene) is responsible for inactivating glucocor-
ticoids in mineralocorticoid receptor (MR) target tissues (Gross
and Cidlowski, 2008). In the absence of this enzyme, GCs
(corticosterone inmice) activateMRdespite the absence of aldo-
sterone, resulting in hypertension (Stewart et al., 1996). That
Hsd11b2 is an IR1 nGRE-containing gene provides a possible
molecular explanation for GC therapy-induced hypertension.Toward Improved Anti-Inflammatory Dissociated
Glucocorticoid Agonists
Our study indicates that previous attempts, aimed at identifying
GC analogs exhibiting a dissociated profile likely failed because
such GCs had kept their IR nGRE-mediated repression activity.
Thus, improved screenings for anti-inflammatory dissociated
GCs should look for compounds that would repress gene
expression through tethered transrepression, while lacking IR
nGRE-mediated transrepression and (+)GRE-mediated transac-
tivation activities. Our luciferase reporter plasmids could be(H) ChIP analysis of epidermis from WT mice topically-treated with Dex and RU
indicated.
Values are given as the mean ± SEM.useful for such screenings, as well as for characterizing the
mode of action of some non-GC-derived compounds that may
exhibit some of the beneficial therapeutic activities of dissoci-
ated GCs, but be devoid of their detrimental effects (De
Bosscher and Haegeman, 2009).
Conclusion
That a single hormone (cortisol in human and corticosterone in
rodents) bound to a single nuclear receptor, the glucocorticoid
receptor, can finely and coordinately tune transcription of thou-
sands of genes involved in vital functions, in essentially all cells
throughout the life span of vertebrates, remains an amazing
conundrum to be solved at the molecular level. We demonstrate
here the existence of a novel mechanism of control of gene
expression by GCs, namely GC-induced transrepression
through direct binding of agonist-liganded GR associated with
SMRT/NCoR corepressors to an evolutionary conserved family
of ‘‘simple’’ negative DNA binding sites (IR nGREs), unrelated
to the ‘‘simple’’ (+)GRE binding site family. Such a mechanism
which, to our best knowledge, has no precedent in the nuclear
receptor field, introduces a new paradigm for GR action through
which variations in levels of a single ligand can concomitantly
differentially turn on or off two sets of genes widely differing in
their response element DNA sequences [(+)GRE and IR nGRE,
respectively]. This possibility remarkably suits GR signaling, as
GC adrenal secretion varies in a circadian and stress-related
fashion. Indeed, increases in GC levels will concomitantly turn
on the expression of (+)GRE-containing genes, and turn off the
expression of IR nGRE-containing genes, whereas decreases
in GC levels will have the opposite effects on the two sets of
genes, thus enabling them to synergistically contribute to the
control of given physiological events (e.g., stress-induced hyper-
glycemia).Whether the different cell-specificGR isoforms (Gross
and Cidlowski, 2008) generate additional specificity in these
controls remains to be seen, as well as the possible existence
of similar mechanisms of control of gene expression by other
members of the NR superfamily.
EXPERIMENTAL PROCEDURES
Additional details on methods are available online in Extended Experimental
Procedures.
Mice
For topical treatment, 1 nmole (nm)/cm2 MC903, at-RA or TPA; 6 nm/cm2 FA,
Dex or RU24858; and 90 nm/cm2 RU486 were used. For systemic use,
100 ng/kg body weight active Vit D3, 8 mg/kg Dex and 64 mg/kg RU486
was intraperitoneally injected. GRdim mice were from the European Mouse
Mutant Archives (EM:02123). Breeding, maintenance and experimental
manipulation of mice were approved by the Animal Care and Use Committee
of the IGBMC.
ChIP Assay
Isolated epidermis and intestinal epithelial cells were crosslinked in 1% form-
aldehyde followed by ChIP assay, as reported (Vaisanen et al., 2005).24858 for 18 hr, showing binding to IR nGRE or (+) GRE regions of genes as
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Table 2. Side Effects Generated by GC Therapy Are Related to Those Produced by GC-Induced Transrepression of IR
nGRE-Containing Genes
(A) IR nGRE-Containing Genes Whose GC-Induced Transrepression Could Generate Side Effects Related to Those Produced by GC Therapy (see
also Table S3)
Debilitating Side Effects upon
GC Therapy
Gene Symbol Gene Name a b References
Skin atrophy, bruising, thinning,
brittle skin, and disturbed wound
healing (Schacke et al., 2002)
Krt 14, Krt 5 Keratin 14 (IR1), Keratin 5
(IR1)
+  Ramot et al., 2009, This study
(see Figures 3A and 3H)
TGFb1 Transforming growth factor
beta 1 precursor (IR1)
+  Frank et al., 1996
Smad4 SMAD family member 4 (IR2)  + Chen et al., 2000
Tnc Tenascin C (IR2) +  Fassler et al., 1996
Trpv3 Transient receptor potential cation
channel subfamily V member 3 (IR2)
 + Cheng et al., 2010
Ccnd1 Cyclin D1 (IR0) + + This study (see Fig. S3A)
Cdk4 Cyclin-dependent kinase 4 (IR2) + + Rogatsky et al., 1999
Impaired skeletal growth and
osteoporosis (Schacke et al., 2002,
Kleiman and Tuckermann, 2007)
Tnfrsf11b Osteoprotegerin (IR2) + + Sasaki et al., 2001
Bcl2 Bcl- 2 (IR1) +  Mocetti et al., 2001
Bcl2l1 Bcl- XL (IR1) +  Lu et al., 2007
TGFb1 Transforming growth factor
beta 1 precursor (IR1)
 + Geiser et al., 1998
Smad 4 SMAD family member 4 (IR2)  + Tan et al., 2007
Ghr Growth hormone receptor (IR1) + + Gevers et al., 2002
Gnas Adenylate cyclase stimulating
G-alpha protein (IR1)
 + Weinstein et al., 2004
Wnt5a Wingless-related MMTV integration
site 5A (IR1)
 + Yang et al., 2003
Ahsg Alpha -2- HS- glycoprotein precursor (IR0)  + Szweras et al., 2002
Col11a2 Collagen, type XI, alpha 2
chain precursor (IR2)
 + Li et al., 2001
Hyperglycemia and diabetes
(Schacke et al., 2002,
Kleiman and Tuckermann, 2007)
Ins Insulin precursor (IR1, IR2) + + Delaunay et al., 1997,
This study (see Figure 3H)
Insr Insulin receptor (IR1) + + Caro and Amatruda., 1982,
This study (see Fig. 3H)
Muscle atrophy/myopathy
(Schakman et al., 2008a)
ctnnb1 Beta –catenin (IR1) + + Schakman et al., 2008b
Akt1 Protein kinase B (IR2)  + Schakman et al., 2008a
Tpm2 Tropomysin beta chain (IR1)  + Ochala et al., 2007
Impaired HPA axis and adrenal
insufficiency (Schacke et al., 2002)
Mc2r ACTH receptor (IR1) + + Chida et al., 2007, This study
(see Figure 3H)
Mrap ACTH receptor accessory
protein (IR1)
+ + Metherell et al., 2005,
This study (see Figure 3H)
Circadian rhythm disorder,
metabolic syndrome,
bipolar disorder, and mania
(Bechtold et al., 2010,
Duez and Staels, 2008)
Clock Circadian locomoter output
cycle kaput protein (IR1)
 + Roybal et al., 2007
Nr1d1 Reverba (IR1) +  Torra et al., 2000;
Preitner et al., 2002;
This study (see Figure 3H)
Rora RORa (IR2) +  This study (see Figures S4B
and S4C)
Anxiety and depression
(Schacke et al., 2002)
Ucn2 Urocortin 2 (IR1) + + Chen et al., 2004, 2006;
Neufeld-Cohen et al., 2010
Crhr2 Corticotropin releasing
hormone receptor 2 (IR1)
 + Bale et al., 2000
Hypertension
(Schacke et al., 2002)
Hsd11b2 Corticosteroid
11-beta-dehydrogenase
isozyme 2 (11b-HSD2) (IR1)
+ + Stewart et al., 1996,
This study (see Figure 3A)
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Table 2. Continued
(B) IR nGRE- Containing Genes Involved in GC-Anti-Inflammatory Therapy (see also Table S3)
Gene Symbol Gene Name* Gene Symbol Gene Name*
C1qb Complement C1q subcomponent
subunit B Precursor (IR2)
Il16 Interleukin-16 Precursor (IR1)
C1ql1 C1q-related factor Precursor (IR1) Il17rb Interleukin-17 receptor b (IR1)
C3 Complement C3 Precursor (IR1) Il11ra1 Interleukin-11 receptor (IR1)
Cfd Complement factor D Precursor (IR1) Il17b Interleukin-17b Precursor (IR1)
Il6 Interleukin-6 Precursor (IR1) Il17f Interleukin-17f Precursor (IR1)
Il20 Interleukin-20 Precursor (IR2) Il28a Interleukin-28a Precursor (IR1)
Ccr10 C-C chemokine receptor type 10 (IR2) Il28b Interleukin-28b Precursor (IR1)
Stat3 Signal transducer and activator of
transcription 3 (IR2)
Il24 Interleukin-24 Precursor (IR1)
Nfatc1 Nuclear factor of activated T-cells,
cytoplasmic 1 (IR1)
Il34 Interleukin-34 Precursor (IR1)
Il8ra Interleukin-8 receptor a (IR1) Il1rn Interleukin-1 receptor antagonist protein
Precursor (IR2)
Il12rb1 Interleukin-12 receptor b1 (IR1) Il22ra1 Interleukin-22 receptor a1 (IR1)
Il17ra Interleukin-17 receptor a (IR1) TSLP Thymic Stromal Lymphopoietin (IR1)
a Geneswhose expression is known to be decreased uponGC treatment. bGenes, whose decreased expression is known to generate effects related to
those produced by GC treatment. (IR0), (IR1), and (IR2) indicate the type of nGRE motif present in that gene. Asterisk denotes that all of these genes
also contain NFkB and AP1 binding sites.Nuclear Run-on, EMSA, 3C and Luciferase Assays
Nuclear Run-on and EMSA (Carey and Smale, 2001), 3C (Liu and Garrard,
2005) and Luciferase assays (Promega kit) were as described.
Real-Time PCR
Total RNAwas reverse transcribed using hexamers, followed byQ-PCR, as re-
ported (Li et al., 2005).
siRNA Treatment
ON-TARGETplus SMARTpool siRNAs against SMRT (L-020145-01-0050) and
NCOR (L-003518-00-0050, Dharmacon) were transfected into A549 cells
using Lipofectamine 2000 (Invitrogen), according to manufacturer’s
instruction.
Statistics
Data are represented as mean ± SEM of at least three independent experi-
ments, and were analyzed using sigmastat (Systat Software) by the Student
t test. p < 0.05 was considered significant.
Bioinformatics Analysis
hg19 (human) and mm9 (mouse) repeat masked genome assembly was used
to identify genome wide distribution of IR nGRE motifs. Gene functional anno-
tation was performed using DAVID program. Details in Extended Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and six tables and can be found with this article online at doi:10.1016/j.
cell.2011.03.027.
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